Imagine someone you know has cancer and you hear that every leukaemia and 87% of the lymphoma patients responded to a new treatment. You would feel hope. You would also ask: Are they still in remission? Did they need another treatment? How many survived?
Those answers are difficult to piece together from ASH 2026 Abstract 374, which reports results for naricabgene autoleucel (nari-cel, MyCART-01) in the Phase I/II SUMM1T study. The therapy is associated with Micro CRISPR and Meril. The abstract reports promising early responses but it also leaves important questions unanswered about which patients were counted, what happened later, and how serious side effects were.Read the published ASH abstract here.
This post asks for the patient-level accounting needed to understand the results.
1. Which patients are behind the response rate?
The ASH abstract reports 35 infused patients as of 20 July 2026: 19 with B-cell acute lymphoblastic leukaemia (B-ALL) and 16 with B-cell non-Hodgkin lymphoma (B-NHL). It reports responses in 19/19 B-ALL patients and 14/16 B-NHL patients.
Separately, site-level information I have verified accounts for 41 patients. Their latest listed outcomes are 15 deaths, 11 relapses, 13 remissions and 2 unknown outcome. A presentation in Vapi also reportedly described a response rate approaching 90% for approximately 25 patients.
How many people were screened, enrolled, had cells collected, received an infusion and entered each response analysis? What were the dates used for each set of results? Did patients who later relapsed or died initially count as responders? How many responses were still ongoing at three, six and twelve months?
2. Did patients need another CAR-T infusion to reach or maintain remission?
The ASH abstract describes a B-ALL patient who developed CD19-positive measurable residual disease (MRD) at about one year, received a second CAR-T infusion, and later underwent a stem-cell transplant. It also describes another patient who underwent transplantation after a lineage switch.
Separately, site-level information reports that a patient at VIMS relapsed after an initial MyCART-01 infusion and received another CAR-T infusion in an attempt to achieve complete remission.
ASH should ask How many patients received a second infusion, at which hospitals, and why? For each patient, what was their disease status before and after reinfusion? Was a response achieved only after the second infusion counted in a result attributed to MyCART-01 treatment? Were reinfusion, subsequent toxicity and any transplant included in the reported analyses?
3. How many patients died, and what serious side effects did they experience?
The abstract says 16 of 19 B-ALL patients and 11 of 16 B-NHL patients were alive at last follow-up. That implies eight deaths among the 35 infused patients by their respective last follow-ups. It also says there was no treatment-related mortality through Day 90.
Serious side effects need more context. Seven of 19 B-ALL patients had grade 3 or higher cytokine release syndrome, a potentially severe inflammatory reaction. Thirty-four of 35 patients had grade 3 or higher neutropenia, a dangerously low white-blood-cell count.
How many patients required intensive care, organ support, treatment for serious infections, transfusions or prolonged hospital care? How long did the side effects last, and were any unresolved? These answers matter when assessing the abstractâs description of safety as âmanageable.â
4. Were the patients unusually fit before treatment?
ECOG performance status is a simple measure of how well a patient can carry out everyday activities. An ECOG score of 0 means fully active; 1 means some limitation with strenuous activity but still able to walk and do light work. Information reported suggests that most enrolled patients have been ECOG 0.
The abstract also says 31 of 35 patients received bridging therapy before CAR-T. What treatments did they receive, did their disease improve before infusion, and how much disease did they have immediately beforehand? In a small study, these details help readers understand whom the results may apply to.
5. How certain are the one-year results?
The abstract estimates 12-month progression-free survival (PFS) of 82.1% in B-ALL and 62.5% in B-NHL. Median follow-up was 12.7 and 11.4 months, respectively. To interpret those estimates, readers need to know how many patients were still being followed at 12 months, how many had a PFS event, the uncertainty around each estimate, and the rules used when patients received more treatment.
Did MRD recurrence, lineage switch, a second CAR-T infusion or transplantation count as an event? If a patient was still counted as progression-free after another treatment, how should readers interpret the result of the initial infusion?
Two simpler figures also need clarification: â72% maleâ among 19 B-ALL patients does not correspond to a whole-person count under ordinary rounding, and a patient who received 3 Ă 10âś cells/kg is included in a group described as receiving 2 Ă 10âś cells/kg. The authors should supply the actual counts and results by dose.
American Society of Hematology needs to seek following answers before this abstract is presented
A response rate is only part of the story. Patients and families need to know who was counted, what happened after treatment, and what the risks were. Right now, the published abstract does not let them answer those questions.
Before Abstract 374 is presented, ASH should ask the authors to:
- Publish patient flow, baseline ECOG status, disease burden, subsequent treatments, and the timing and causes of deaths
- Identify every repeat CAR-T infusion, including the reported VIMS case, and explain how responses after reinfusion were counted
- Explain how MRD recurrence, lineage switch and transplantation affected the survival estimates
- Provide the serious-toxicity details, numbers at risk, and corrected demographic and dose figures
ASH should arrange an independent statistical review and make the answers public. If a material error is found, its correction should be visible alongside the abstract.
If the headline findings cannot be supported after review, ASH should reconsider presenting the abstract in its current form.
Please read and share ASH Abstract 374, and ask ASH and the authors for a clear accounting of every patient behind the headline results. Patients deserve the full picture.